Beacon Therapeutics
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING0
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| rAAV2tYF-GRK1-RPGR NCT06333249 |
P2 | Active, not recruiting | X-Linked Retinitis Pigmentosa | 14 | 2023-04-11 |
| HORIZON NCT03316560 |
P1/2 | Active, not recruiting | X-Linked Retinitis Pigmentosa | 29 | 2023-11-09 |
| AGTC-501 (high dose and standard corticosteroid regimen) NCT06275620 |
P2 | Enrolling by invitation | X-Linked Retinitis Pigmentosa | 24 | 2025-11 |
| rAAV2tYF-GRK1-hRPGRco NCT04850118 |
P2/3 | Active, not recruiting | X-Linked Retinitis Pigmentosa | 85 | 2026-06-30 (+30 mo) |
| Landscape NCT07174726 |
P2 | Active, not recruiting | X-Linked Retinitis Pigmentosa (XLRP) | 10 | 2029-12-31 (+30 mo) |